Sebastian Kurz, MD, PhD, FCCP
Associate Professor TermCards
About
Research
Publications
2026
To the Editor: Severe Necrotizing Lung Infections: Definitions and Therapeutic Indications
Rakovich G, Kurz S. To the Editor: Severe Necrotizing Lung Infections: Definitions and Therapeutic Indications. Journal Of Intensive Care Medicine 2026, 41: 916-916. PMID: 42351379, DOI: 10.1177/08850666261453827.Commentaries, Editorials and LettersSynergistic activity of dual β-lactams against Mycobacterium avium complex
Shin E, Dousa K, Nantongo M, Kurz S, Holland S, Kreiswirth B, Bonomo R. Synergistic activity of dual β-lactams against Mycobacterium avium complex. Microbiology Spectrum 2026, 14: e04001-25. PMID: 41914629, PMCID: PMC13141822, DOI: 10.1128/spectrum.04001-25.Peer-Reviewed Original Research
2025
The Mitral Valve and the Lungs
Pradhan N, Wessler B, Hill N, Kurz S. The Mitral Valve and the Lungs. Chest 2025, 169: 744-753. PMID: 41297586, DOI: 10.1016/j.chest.2025.11.016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
Dousa K, Shin E, Kurz S, Rubin E, Holland S, Olivier K, Daley C, Kreiswirth B, Pottinger P, Bonomo R. The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials. Clinical Infectious Diseases 2025, 82: e135-e145. PMID: 41026774, PMCID: PMC13375569, DOI: 10.1093/cid/ciaf547.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsExploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis
Nantongo M, Nguyen D, Shin E, Bethel C, Taracila M, Dousa K, Li Q, Fletcher S, Kurz S, Kreiswirth B, Boom W, Holland S, Rubin E, Bonomo R. Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis. MBio 2025, 16: e01372-25. PMID: 40637416, PMCID: PMC12345272, DOI: 10.1128/mbio.01372-25.Peer-Reviewed Original Research
2024
Durlobactam in combination with β-lactams to combat Mycobacterium abscessus
Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D, Akusobi C, Kurz S, Plummer M, Daley C, Holland S, Rubin E, Bulitta J, Boom W, Kreiswirth B, Bonomo R. Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrobial Agents And Chemotherapy 2024, 69: e01174-24. PMID: 39714147, PMCID: PMC11823594, DOI: 10.1128/aac.01174-24.Peer-Reviewed Original ResearchSynergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus
Dousa K, Shin E, Kurz S, Plummer M, Nantongo M, Bethel C, Taracila M, Nguyen D, Kreiswith B, Daley C, Remy K, Holland S, Bonomo R. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. MBio 2024, 15: e00609-24. PMID: 38742824, PMCID: PMC11237399, DOI: 10.1128/mbio.00609-24.Peer-Reviewed Original ResearchDurlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis
Nantongo M, Nguyen D, Bethel C, Taracila M, Li Q, Dousa K, Shin E, Kurz S, Nguyen L, Kreiswirth B, Boom W, Plummer M, Bonomo R. Durlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infectious Diseases 2024, 10: 1767-1779. PMID: 38619138, DOI: 10.1021/acsinfecdis.4c00119.Peer-Reviewed Original Research
2023
Eradicating Pulmonary Mycobacterium abscessus: The Promise of Dual β-Lactam Therapy
Alahmdi B, Dousa K, Kurz S, Kaufman A, Bonomo R, Taimur S. Eradicating Pulmonary Mycobacterium abscessus: The Promise of Dual β-Lactam Therapy. Open Forum Infectious Diseases 2023, 10: ofad312. PMID: 37383246, PMCID: PMC10296056, DOI: 10.1093/ofid/ofad312.Peer-Reviewed Original ResearchPilot Evaluation of a Management Toolkit for Airway Clearance Therapy in Bronchiectasis (IMPACT BE)
Solomon G, Barker A, McSpiritt E, Marikovics S, Quittner A, Barker A, Daley C, Daniels L, Jones J, McShane P, Quittner A, Solomon G, Winthrop K, Walker P, Kurz S, DePalo L, Haworth C, Belkin R, Daley C, Khabbaza J, Dasenbrook E. Pilot Evaluation of a Management Toolkit for Airway Clearance Therapy in Bronchiectasis (IMPACT BE). ATS Scholar 2023, 4: 76-86. PMID: 37089683, PMCID: PMC10117526, DOI: 10.34197/ats-scholar.2022-0061in.Peer-Reviewed Original Research
News
News
- October 01, 2025
Yale PCCSM Faculty Earn National Recognition at CHEST Annual Meeting
- April 14, 2025
Expanded Yale Center Enhances Access to Asthma, COPD, and Bronchiectasis Diagnosis, Care, and Research
- January 02, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (January 2025)
- November 25, 2024
Celebrating Leadership and Education: Yale Faculty Recognized at CHEST Annual Meeting